行情

MREO

MREO

MEREO BIOPHARMA
NASDAQ

实时行情|Nasdaq Last Sale

3.380
-0.070
-2.03%
已收盘, 16:00 09/13 EDT
开盘
3.400
昨收
3.450
最高
3.400
最低
3.370
成交量
1,291
成交额
--
52周最高
8.48
52周最低
2.180
市值
7,350.48万
市盈率(TTM)
-1.4721
分时
5日
1月
3月
1年
5年

MREO 新闻

  • 沪指高开震荡 沙特石油设施遇袭、油价一度跳升20%
  • 新浪财经.34分钟前
  • 分析师:沙特石油遇袭重创供应 油价100美元或重现
  • 新浪财经综合.2小时前
  • iPhone11发布意味着电子行业行情已结束?
  • 第一财经.2小时前
  • 美电力公司就加州山火达成巨额和解 将支付110亿美元
  • 中国新闻网.3小时前

更多

所属板块

生物技术和医学研究
+0.20%
制药与医学研究
-0.38%

热门股票

名称
价格
涨跌幅

MREO 简况

Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.
展开

Webull提供Mereo BioPharma Group PLC的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。